General information, not legal or regulatory advice. Sources checked on 16 October 2026. bioaccess® is not affiliated with CogenTech, LA Research S.A.S. or their affiliates. Names belong to their owners and are used solely to identify them. Every statement about CogenTech, LA Research S.A.S. or their affiliates comes from its own public website or from public INVIMA records linked below. Offers change, so confirm current terms with each provider.
Many sponsors know CogenTech as a U.S. MedTech program management organization. In Colombia, its studies appear in INVIMA records under a local company, LA Research S.A.S. This page explains that link, lists what the public record shows, and compares it with bioaccess®, Latin America’s specialist first-in-human device CRO. For the general comparison, see bioaccess® vs CogenTech.
Who CogenTech is
CogenTech Medical & Digital Innovation describes itself as a project management organization that leads clinical trials, with a digital platform. Its LinkedIn page lists headquarters in Mahwah, New Jersey, a founding year of 2020, and a team spread across Colombia, the United States, Chile, the Dominican Republic and Spain, with about half of the staff in Colombia.
LA Research S.A.S. in INVIMA records
- AbSolutions Med REBUILD bioabsorbable feasibility study, Clínica Las Américas, Medellín: approved, Acta 21 of 2021, numeral 3.1.
- SpectraWAVE OCT-NIRS first-in-human study, Angiografía de Occidente, Cali: approved, Acta 8 of 2022, numeral 3.1.
- Imperative Care ADVANCE intracranial stent study: LA Research was the initial CRO; approved in Actas 13B and 14 of 2023.
- AbSolutions REBUILD CTP-0002: not approved, Acta 11 of 2023, numeral 3.1.
LA Research is also one of the most frequent filers on the INVIMA device committee agenda (amendments, safety reports and other items) from 2021 to 2025. Sources: approved-studies registry, not-approved registry, device committee actas.
Colombia context
INVIMA’s own registries list 15 device clinical studies approved from 2021 to October 2025 (5 in 2021, 4 in 2022, 3 in 2023, 3 in 2024 and none in 2025 through October). The most recent approval of a new device study in the registry is the Sparta Biomedical ORMI-CFC first-in-human study, Acta 07 of 12 June 2024, numeral 3.13. INVIMA has not yet published any 2026 device committee minutes. Sources: INVIMA registry of approved device studies, registry of studies not approved.
When each fits
If you want a PMO layer coordinating a multi-year program from first-in-human through pivotal, CogenTech presents itself as built for that. If your next milestone is a clean, FDA-bridgeable first-in-human dataset on a startup timeline, bioaccess® is built for that, with Bioaccess Colombia SAS handling INVIMA in-country.
Frequently asked questions
What is LA Research SAS?
LA Research S.A.S. is the Colombian company that appears in INVIMA records as the CRO for studies associated with CogenTech. INVIMA’s registry of approved device studies lists the CRO as “COGENTECH, TECHNOLOGIES-LA” for those studies.
Which INVIMA device studies did CogenTech / LA Research run?
INVIMA’s registry lists LA Research / CogenTech as CRO for the AbSolutions REBUILD feasibility study (approved Acta 21 of 2021), the SpectraWAVE OCT-NIRS first-in-human study in Cali (approved Acta 8 of 2022) and, as initial CRO, the Imperative Care ADVANCE intracranial stent study (approved 2023). INVIMA did not approve a second AbSolutions protocol, CTP-0002 (Acta 11 of 2023).
Is CogenTech a CRO or a PMO?
CogenTech describes itself as a MedTech program management organization (PMO) that leads clinical trials, with its LearUp platform. Its LinkedIn page lists headquarters in Mahwah, New Jersey, and a team spread across Colombia, the United States, Chile, the Dominican Republic and Spain.
How is bioaccess® different?
bioaccess® is Latin America’s specialist first-in-human device CRO. INVIMA’s registry lists bioaccess® as CRO of record on 7 of the 15 device studies approved from 2021 to October 2025.
Related pages
- bioaccess® vs CogenTech
- Clinical trials in Colombia
- CRO in Colombia
- First-in-human trials in Colombia
- INVIMA clinical trial approval process
- Clinical trial cost in Colombia
Next step
Comparing CROs for a Colombian study? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.